Business
Med BioGene Inc. signs letter of intent with the Ontario Institute for Cancer Research
Med BioGene Inc. signs letter of intent with the Ontario Institute for Cancer Research.
About this update from Many Bright Ideas Technologies Inc
[{"type":"text","content":"\n\n\n\n\nVANCOUVER, June 23 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased\nto announce that it has signed a letter of intent with the Ontario Institute\nfor Cancer Research (OICR) pursuant to which the Ontario Tumour Bank, an\ninitiative of the OICR, will provide to MBI tumour tissue samples of confirmed\nlymphoma patients. Such samples may also include normal adjacent tissue and/or\nbuffy coat samples.\nMBI will use such samples to undertake further testing of its Diagnostic\nLymphoma Bioarray. In 2004, MBI filed a patent application in the United\nStates in respect of its Hematological Cancer Profiling System relating to its\nDiagnostic Lymphoma Bioarray and Diagnostic Leukemia Bioarray.\nReceipt of the samples is subject to, among other things, the parties\nexecuting a material transfer agreement and MBI receiving the approval of the\nTissue Ethics Committee, a sub-committee of the Ontario Cancer Research Ethics\nBoard.\n\"Our relationship with the Ontario Institute for Cancer Research and\nreceipt of the tissue samples from the Ontario Tumour Bank will be of great\nimportance as Med BioGene continues to develop and test its Diagnostic\nLymphoma Bioarray\" stated Erinn Broshko, Chief Executive Officer of MBI. \"We\nare looking forward to receiving the approval of the Tissue Ethics Committee\nand aggressively moving forward with the development of our product.\"\n\nAbout Med BioGene\n\nMBI is a biotechnology company with advanced research expertise in gene\nexpression technology. MBI's mission is to become the market leader in the\nsupply of content for molecular-based diagnostic micro arrays. MBI intends to\nfulfill this mission by developing and marketing genetic content for\nmolecular-based human diagnostic tests. Molecular diagnostics, based on\ngenetic expression, is a developing technology field that has the potential to\nreplace certain of today's standard diagnostic tests. MBI intends to utilize\nits expertise in gene expression, bioinformatics and micro arrays to develop\nthe diagnostic tests' genetic content. From the tens of thousands of genes in\nthe human genome, MBI is identifying those genes, known as \"bio markers,\"\nwhich mark the presence of various disease conditions.\nMBI's initial focus will be developing diagnostic tests for certain types\nof cancer, specifically lymphoma and leukemia. In the f...